文献速递治疗药物监测与药物基因组学抗菌药物管理

生物标志物引导的抗菌治疗个体化

Biomarker-Guided Individualization of Antibiotic Therapy.
PubMed 文献 · Clin Pharmacol Ther · 2021-03-02

本文讨论利用宿主反应生物标志物(如CRP、降钙素原、IL-6、presepsin)指导抗菌治疗个体化的现有证据与建模方法,并以脓毒症患者降钙素原动态的定量刻画为例,说明药理学建模与系统药理学建模如何进一步表征治疗反应生物标志物数据。

要点

  • 治疗药物监测仍是优化抗菌药物暴露、减少治疗失败与毒性的重要手段。
  • 宿主反应生物标志物可能为抗菌治疗个体化提供重要信息。
  • 需更好理解免疫系统、病原体、药物与生物标志物间的复杂交互。

核心结论

  • 生物标志物策略可能是进一步量化和监测抗菌治疗反应、减少患者间治疗反应变异的强大工具。

研究设计与样本

  • 本文为教程性综述,讨论现有生物标志物方法用于指导抗菌治疗的证据,并纳入临床前、健康志愿者及患者研究的治疗反应生物标志物数据。

主要发现

  • 宿主反应生物标志物如CRP、降钙素原、IL-6和presepsin可能携带可用于治疗个体化的重要信息。
  • 以脓毒症患者为例,定量刻画了降钙素原动态与抗菌治疗的关系。

临床怎么用

  • 临床可参考治疗药物监测优化抗菌药物暴露,并关注宿主反应生物标志物在治疗反应监测中的潜在价值。

局限性

  • 需更好理解免疫系统、病原体、药物与生物标志物之间的复杂交互,才能实现生物标志物引导的个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment failure of antibiotic therapy due to insufficient efficacy or occurrence of toxicity is a major clinical challenge, and is expected to become even more urgent with the global rise of antibiotic resistance. Strategies to optimize treatment in individual patients are therefore of crucial importance. Currently, therapeutic drug monitoring plays an important role in optimizing antibiotic exposure to reduce treatment failure and toxicity. Biomarker-based strategies may be a powerful tool to further quantify and monitor antibiotic treatment response, and reduce variation in treatment response between patients. Host response biomarkers, such as CRP, procalcitonin, IL-6, and presepsin, could potentially carry significant information to be utilized for treatment individualization. To achieve this, the complex interactions among immune system, pathogen, drug, and biomarker need to be better understood and characterized. The purpose of this tutorial is to discuss the use and evidence of currently available biomarker-based approaches to inform antibiotic treatment. To this end, we also included a discussion on how treatment response biomarker data from preclinical, healthy volunteer, and patient-based studies can be further characterized using pharmacometric and system pharmacology based modeling approaches. As an illustrative example of how such modeling strategies can be used, we describe a case study in which we quantitatively characterize procalcitonin dynamics in relation to antibiotic treatments in patients with sepsis.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Aulin LBS, de Lange DW, Saleh MAA, et al. Biomarker-Guided Individualization of Antibiotic Therapy. Clin Pharmacol Ther. 2021. PMID: 33559152. doi:10.1002/cpt.2194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。